Eli Lilly and Co (NYSE:LLY) has been given a consensus rating of “Hold” by the twenty-one analysts that are covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $93.28.
A number of equities research analysts recently commented on the company. Jefferies Group reiterated a “buy” rating and issued a $91.00 target price on shares of Eli Lilly and in a research report on Friday. TheStreet downgraded Eli Lilly and from a “b” rating to a “c” rating in a research report on Monday, March 5th. JPMorgan Chase & Co. set a $105.00 target price on Eli Lilly and and gave the stock a “buy” rating in a research report on Monday, February 26th. Credit Suisse Group reiterated a “hold” rating and issued a $80.00 target price on shares of Eli Lilly and in a research report on Friday, February 2nd. Finally, Bank of America decreased their target price on Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating on the stock in a research report on Thursday, February 1st.
Shares of LLY stock traded down $1.77 during trading on Friday, hitting $74.76. The stock had a trading volume of 4,298,117 shares, compared to its average volume of 4,542,241. Eli Lilly and has a fifty-two week low of $73.69 and a fifty-two week high of $89.09. The stock has a market capitalization of $83,846.11, a P/E ratio of -373.78, a price-to-earnings-growth ratio of 1.39 and a beta of 0.28. The company has a quick ratio of 1.01, a current ratio of 1.32 and a debt-to-equity ratio of 0.85.
In other Eli Lilly and news, insider Donald A. Zakrowski sold 860 shares of the business’s stock in a transaction that occurred on Thursday, March 1st. The stock was sold at an average price of $76.50, for a total transaction of $65,790.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Joshua L. Smiley sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, March 16th. The stock was sold at an average price of $79.20, for a total value of $237,600.00. Following the sale, the chief financial officer now directly owns 20,029 shares in the company, valued at $1,586,296.80. The disclosure for this sale can be found here. Insiders have sold 15,261 shares of company stock worth $1,225,085 over the last three months. 0.20% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in LLY. Arrowstreet Capital Limited Partnership grew its stake in shares of Eli Lilly and by 1,327.4% during the second quarter. Arrowstreet Capital Limited Partnership now owns 1,212,824 shares of the company’s stock valued at $99,815,000 after buying an additional 1,127,856 shares during the last quarter. Sather Financial Group Inc purchased a new stake in shares of Eli Lilly and in the second quarter valued at approximately $346,000. Princeton Portfolio Strategies Group LLC boosted its holdings in shares of Eli Lilly and by 0.3% in the second quarter. Princeton Portfolio Strategies Group LLC now owns 17,860 shares of the company’s stock valued at $1,470,000 after purchasing an additional 53 shares during the period. Coldstream Capital Management Inc. boosted its holdings in shares of Eli Lilly and by 23.4% in the second quarter. Coldstream Capital Management Inc. now owns 2,927 shares of the company’s stock valued at $241,000 after purchasing an additional 555 shares during the period. Finally, Laurel Wealth Advisors Inc. boosted its holdings in shares of Eli Lilly and by 8.3% in the second quarter. Laurel Wealth Advisors Inc. now owns 4,954 shares of the company’s stock valued at $407,000 after purchasing an additional 379 shares during the period. 77.62% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This piece of content was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3297366/eli-lilly-and-co-lly-given-consensus-recommendation-of-hold-by-brokerages.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.